Recurrent Pericarditis Woes; Sluggish Cardiovascular Trials; Bargain-Rate TAVR

A case report described carotid arterial thrombosis discovered in a 31-year-old man following his first dose of the AstraZeneca adenovirus vector COVID-19 vaccine. (Neurology)

The incidence of myocarditis among teenage boys with COVID-19 is six times higher than what has been reported after mRNA-based COVID vaccination, according to a U.S. preprint study in medRxiv.

Patients often fail to control recurrent pericarditis with corticosteroid and colchicine use. (Journal of the American Heart Association)

Primary care often dropped the ball in recognizing heart failure, leaving patients — especially women and Black patients — to receive their diagnosis at the emergency department or during hospitalization. (Circulation: Heart Failure)

North American research sites took nearly 8 months from study protocol delivery to first participant enrollment in large cardiovascular trials conducted from 2004 t0 2017. (JAMA Network Open)

Adults who were born small tend to have markedly lower exercise capacity. (JAMA Cardiology)

In transcatheter aortic valve replacement, operators going the minimalist route managed to shave off more than $10,000 in hospitalization costs and reduce pacemaker rates, according to Edwards Lifesciences.

Angiotensin receptor blockers were just as effective as angiotensin-converting enzyme inhibitors in a retrospective head-to-head comparison — with fewer side effects such as angioedema and cough, to boot. (Hypertension)

Cardiac implantable electronic devices wrapped in the bioabsorbable, antibacterial Tyrx envelope were less likely to cause major infections among patients who developed hematomas after device placement, Medtronic said.

Vericiguat (Verquvo) is now approved in Europe as a treatment for adults with reduced ejection fraction who were stabilized after a recent decompensation event requiring intravenous therapy, Bayer announced.

The American College of Cardiology announced that it is teaming up with ARMUS, a data sciences firm, to offer localized quality improvement training to hospitals.

Cardiovascular disease and a bottle of wine per week: a good combination? (BMC Medicine)

Implantable cardioverter-defibrillator recipients who exercised more tended to have better survival outcomes, observational data suggested. (Circulation: Cardiovascular Quality and Outcomes)

More than one in five people receiving lytic therapy for deep vein thrombosis in the lower extremities ended up with acute kidney injury, according to the Society for Vascular Surgery.

For stroke patients, race and driving distance are among the predictors of longer time to arrival at the hospital, according to research presented at the Society of NeuroInterventional Surgery annual meeting.

Operators performing cardiac ablation rated Pure EP software signals as similar or better than existing mapping systems, BioSig Technologies announced. (Seeking Alpha)

AliveCor and Acutus Medical revealed a pilot study to test remote monitoring with the KardiaMobile device to guide catheter-based arrhythmia treatment.

A heart model mimicking physiologic loads was built out of engineered heart tissue. (Science Translational Medicine)

A California-based interventional cardiologist will pay a $2 million settlement for allegedly operating a kickback scheme in cahoots with Prime Healthcare Services, the U.S. Department of Justice said.